Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AORT Artivion	$42.01 -2.0%	$32.50	$21.97 ▼ $43.97	$1.98B	1.64	444,866 shs	461,476 shs
GKOS Glaukos	$90.94 +1.6%	$96.74	$77.10 ▼ $163.71	$5.22B	0.78	959,803 shs	842,084 shs
IRTC iRhythm Technologies	$158.52 +0.4%	$146.64	$55.92 ▼ $168.32	$5.09B	1.41	476,835 shs	305,014 shs
STVN Stevanato Group	€22.48 -0.5%	€24.46	€17.12 ▼ €28.00	€6.81B	0.55	339,908 shs	207,834 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AORT Artivion	+0.06%	-0.58%	+40.53%	+47.10%	+70.95%
GKOS Glaukos	-0.50%	+2.91%	-8.48%	-8.23%	-29.79%
IRTC iRhythm Technologies	-1.65%	-1.64%	+15.92%	+11.84%	+141.19%
STVN Stevanato Group	-0.22%	+1.63%	-9.78%	-7.86%	+13.18%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AORT Artivion	3.3388 of 5 stars	2.5	5.0	0.0	0.0	2.3	2.5	1.9
GKOS Glaukos	4.7176 of 5 stars	4.4	4.0	0.0	4.4	3.0	1.7	0.6
IRTC iRhythm Technologies	1.3242 of 5 stars	2.5	1.0	0.0	0.0	3.1	0.8	0.6
STVN Stevanato Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AORT Artivion	3.00	Buy	$39.80	-5.27% Downside
GKOS Glaukos	2.79	Moderate Buy	$127.42	40.11% Upside
IRTC iRhythm Technologies	3.00	Buy	$157.30	-0.77% Downside
STVN Stevanato Group	2.83	Moderate Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest AORT, STVN, IRTC, and GKOS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	GKOS Glaukos	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/13/2025	AORT Artivion	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$32.00 ➝ $38.80
8/8/2025	AORT Artivion	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/8/2025	AORT Artivion	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$35.00 ➝ $41.00
8/8/2025	AORT Artivion	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$33.00 ➝ $42.00
8/8/2025	AORT Artivion	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$36.00 ➝ $40.00
8/8/2025	AORT Artivion	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$32.00 ➝ $45.00
8/1/2025	IRTC iRhythm Technologies	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/1/2025	IRTC iRhythm Technologies	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$145.00 ➝ $190.00
8/1/2025	IRTC iRhythm Technologies	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$139.00 ➝ $170.00
8/1/2025	IRTC iRhythm Technologies	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$130.00 ➝ $180.00

(Data available from 8/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AORT Artivion	$388.54M	5.10	$0.82 per share	51.31	$6.59 per share	6.38
GKOS Glaukos	$383.48M	13.60	N/A	N/A	$13.91 per share	6.54
IRTC iRhythm Technologies	$657.23M	7.75	N/A	N/A	$2.90 per share	54.66
STVN Stevanato Group	€1.19B	5.70	€0.75 per share	29.97	€5.02 per share	4.48

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AORT Artivion	-$13.36M	-$0.42	N/A	84.03	N/A	-4.43%	5.70%	2.29%	11/6/2025 (Estimated)
GKOS Glaukos	-$146.37M	-$1.65	N/A	N/A	N/A	-21.43%	-8.59%	-6.61%	11/3/2025 (Estimated)
IRTC iRhythm Technologies	-$113.29M	-$2.93	N/A	N/A	N/A	-14.06%	-90.03%	-8.52%	10/29/2025 (Estimated)
STVN Stevanato Group	€127.45M	€0.54	41.63	38.76	2.13	11.73%	10.34%	6.21%	N/A

Latest AORT, STVN, IRTC, and GKOS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	AORT Artivion	$0.11	$0.24	+$0.13	$0.03	$107.96 million	$112.97 million
7/31/2025	Q2 2025	IRTC iRhythm Technologies	-$0.53	-$0.32	+$0.21	-$0.44	$173.94 million	$186.69 million
7/30/2025	Q2 2025	GKOS Glaukos	-$0.26	-$0.24	+$0.02	-$0.34	$115.49 million	$124.12 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AORT Artivion	N/A	N/A	N/A	N/A	N/A
GKOS Glaukos	N/A	N/A	N/A	N/A	N/A
IRTC iRhythm Technologies	N/A	N/A	N/A	N/A	N/A
STVN Stevanato Group	N/A	N/A	N/A	N/A	1 Years

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AORT Artivion	0.52	4.78	3.48
GKOS Glaukos	0.09	5.51	4.69
IRTC iRhythm Technologies	6.25	5.02	4.88
STVN Stevanato Group	0.25	1.79	1.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AORT Artivion	86.37%
GKOS Glaukos	99.04%
IRTC iRhythm Technologies	N/A
STVN Stevanato Group	N/A

Insider Ownership

Company	Insider Ownership
AORT Artivion	8.10%
GKOS Glaukos	6.40%
IRTC iRhythm Technologies	1.10%
STVN Stevanato Group	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AORT Artivion	1,600	47.18 million	43.36 million	Optionable
GKOS Glaukos	780	57.35 million	53.68 million	Optionable
IRTC iRhythm Technologies	2,000	32.13 million	31.91 million	Optionable
STVN Stevanato Group	5,521	302.84 million	N/A	Optionable

AORT, STVN, IRTC, and GKOS Headlines

Recent News About These Companies

Deutsche Bank AG Has $19.19 Million Holdings in Stevanato Group S.p.A. (NYSE:STVN)

August 15, 2025 | marketbeat.com

USNA vs. STVN: Which Stock Is the Better Value Option?

August 12, 2025 | zacks.com

93,709 Shares in Stevanato Group S.p.A. (NYSE:STVN) Bought by Zions Bancorporation National Association UT

August 10, 2025 | marketbeat.com

William Blair Cuts Earnings Estimates for Stevanato Group

August 10, 2025 | americanbankingnews.com

Brokers Set Expectations for Stevanato Group Q3 Earnings

August 9, 2025 | marketbeat.com

Blair William & Co. IL Purchases 137,625 Shares of Stevanato Group S.p.A. (NYSE:STVN)

August 9, 2025 | marketbeat.com

William Blair Predicts Stronger Earnings for Stevanato Group

August 8, 2025 | marketbeat.com

Jackson Square Partners LLC Has $23.65 Million Holdings in Stevanato Group S.p.A. (NYSE:STVN)

August 8, 2025 | marketbeat.com

CenterBook Partners LP Raises Stock Position in Stevanato Group S.p.A. (NYSE:STVN)

August 8, 2025 | marketbeat.com

Mutual of America Capital Management LLC Grows Holdings in Stevanato Group S.p.A. (NYSE:STVN)

August 7, 2025 | marketbeat.com

Stevanato Group (NYSE:STVN) Stock Price Down 8.6% - Here's What Happened

August 6, 2025 | marketbeat.com

Stevanato Group (NYSE:STVN) Issues FY 2025 Earnings Guidance

August 6, 2025 | marketbeat.com

Stevanato Group S.p.A.: Stevanato Group Reports Revenue of €280.0 Million for the Second Quarter of 2025

August 6, 2025 | finanznachrichten.de

Stevanato Group Reports Revenue of €280.0 Million for the Second Quarter of 2025

August 6, 2025 | finance.yahoo.com

Stevanato Group (STVN) Q2 Earnings and Revenues Beat Estimates

August 5, 2025 | zacks.com

Stevanato Group Reports Revenue of â‚¬280.0 Million for the Second Quarter of 2025

August 5, 2025 | businesswire.com

Stevanato Group S.p.A.'s (NYSE:STVN) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

August 4, 2025 | finance.yahoo.com

Thornburg Investment Management Inc. Sells 12,214 Shares of Stevanato Group S.p.A. (NYSE:STVN)

July 30, 2025 | marketbeat.com

Premier Fund Managers Ltd Acquires Shares of 34,951 Stevanato Group S.p.A. (NYSE:STVN)

July 30, 2025 | marketbeat.com

Stevanato Group (STVN) Earnings Expected to Grow: Should You Buy?

July 29, 2025 | zacks.com

Royce & Associates LP Sells 44,400 Shares of Stevanato Group S.p.A. (NYSE:STVN)

July 27, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AORT, STVN, IRTC, and GKOS Company Descriptions

Artivion NYSE:AORT

$42.01 -0.84 (-1.95%)

Closing price 03:59 PM Eastern

Extended Trading

$42.02 +0.01 (+0.02%)

As of 05:48 PM Eastern

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Glaukos NYSE:GKOS

$90.94 +1.42 (+1.59%)

Closing price 03:59 PM Eastern

Extended Trading

$88.22 -2.73 (-3.00%)

As of 05:41 PM Eastern

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

iRhythm Technologies NASDAQ:IRTC

$158.52 +0.59 (+0.37%)

Closing price 04:00 PM Eastern

Extended Trading

$158.46 -0.06 (-0.03%)

As of 07:04 PM Eastern

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.

Stevanato Group NYSE:STVN

€22.48 -0.11 (-0.49%)

As of 03:50 PM Eastern

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time